Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including community‑acquired pneumonia, complicated intra‑abdominal infections, complicated skin and soft tissue infections, and acute bacterial sinusitis.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin Kabi is a fluoroquinolone antibacterial indicated for several serious bacterial infections.

- Community‑acquired bacterial pneumonia: provides rapid bactericidal activity to resolve pulmonary infection and improve respiratory function. - Complicated intra‑abdominal infections: achieves broad‑spectrum coverage of aerobic and anaerobic pathogens involved in intra‑abdominal sepsis. - Complicated skin and soft tissue infections: eliminates resistant Gram‑positive and Gram‑negative organisms to promote wound healing. - Acute bacterial sinusitis: eradicates the causative bacteria, relieving sinus inflammation and congestion.

Moxifloxacin Kabi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: often self‑limiting, may be watery. - Headache: transient and usually resolves without intervention. - Injection site reactions: erythema or discomfort at the infusion site.

Serious or Rare Side Effects: - Tendon rupture or tendinitis: especially in the Achilles tendon, may occur during or after therapy. - QT interval prolongation: can precipitate ventricular arrhythmias, particularly in patients with cardiac risk factors. - Severe hypersensitivity reactions: including anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal impairment: monitor renal function and adjust therapy as needed. - History of tendon disorders: avoid use in patients with prior tendon injury or tendon‑related conditions. - QT prolongation risk: obtain baseline ECG and avoid concomitant QT‑prolonging agents. - Concurrent use with antacids containing aluminum or magnesium: separate administration by at least 2 hours to prevent reduced absorption. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin Kabi can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: increased risk of additive toxicity. - Concurrent use with drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase the likelihood of central nervous system adverse effects.

Moderate Interactions (Monitor Closely): - Antacids or supplements containing divalent cations (calcium, iron, magnesium, zinc): may reduce drug absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Theophylline: possible increase in serum theophylline levels; observe for signs of toxicity.